Vanguard Group Inc. Buys 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Vanguard Group Inc. boosted its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,975,655 shares of the company's stock after acquiring an additional 55,283 shares during the quarter. Vanguard Group Inc. owned 4.04% of Enliven Therapeutics worth $44,452,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Lord Abbett & CO. LLC purchased a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $8,199,000. Geode Capital Management LLC grew its holdings in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after purchasing an additional 67,813 shares during the period. Barclays PLC increased its position in Enliven Therapeutics by 295.8% in the third quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after buying an additional 42,012 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Enliven Therapeutics by 107.0% during the 3rd quarter. Wellington Management Group LLP now owns 70,170 shares of the company's stock valued at $1,792,000 after acquiring an additional 36,267 shares during the period. Finally, State Street Corp increased its holdings in Enliven Therapeutics by 2.9% in the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock worth $19,051,000 after acquiring an additional 21,018 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Remove Ads

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $0.14 during mid-day trading on Tuesday, reaching $17.05. The company's stock had a trading volume of 160,946 shares, compared to its average volume of 267,825. The stock has a fifty day moving average of $20.20 and a two-hundred day moving average of $23.24. The firm has a market capitalization of $835.52 million, a PE ratio of -8.97 and a beta of 1.03. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. Analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the transaction, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at approximately $490,590. This trade represents a 12.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the sale, the chief operating officer now owns 329,977 shares in the company, valued at $7,236,395.61. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,751 shares of company stock worth $1,178,263. Insiders own 29.20% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.